![]() |
市場調查報告書
商品編碼
1499541
真菌感染疾病診斷市場:按類型、診斷方法、最終用戶分類 - 全球預測 2024-2030Fungal Infections Diagnosis Market by Type, Diagnostic Method, End-User - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
真菌感染疾病診斷市場規模預計2023年為20.9億美元,預計2024年將達22.3億美元,2030年將達到33.5億美元,複合年成長率為6.96%。
真菌感染疾病(真菌病)是指由真菌(酵母菌和黴菌)引起的感染疾病和疾病。真菌感染疾病最常見於皮膚和指甲,但真菌也會引起口腔、喉嚨、肺部和泌尿道感染疾病。真菌感染疾病包括足癬、香港腳、趾甲真菌、酵母菌病菌感染和掌蹠膿皰病。真菌感染疾病的診斷主要依賴臨床檢體鏡檢、組織病理學檢查、培養、X光檢查、MRI檢查、CT影像檢查等方法。世界各地真菌感染疾病的增加急劇增加了對有效疾病檢測技術的需求。此外,政府努力提高真菌感染疾病管理意識,並努力擴大醫療保健設施的覆蓋範圍,從而提高了真菌感染疾病診斷的採用率。然而,分子和基因真菌感染疾病診斷的複雜性以及熟練醫療臨床人員的缺乏正在阻礙真菌感染疾病診斷解決方案的成長。此外,不準確或不一致的診斷結果以及產品核可的嚴格規定也給真菌感染疾病診斷設備、解決方案和服務帶來了挑戰。然而,主要企業正在迅速增加研發投資,以提高診斷技術的功效和準確性。成像技術的進步將增強遠距離診斷的數位解決方案,而快速診斷技術中人工智慧的引入將提供成長機會。
主要市場統計 | |
---|---|
基準年[2023] | 20.9億美元 |
預測年份 [2024] | 22.3億美元 |
預測年份 [2030] | 33.5億美元 |
複合年成長率(%) | 6.96% |
區域洞察
由於大眾對真菌感染疾病認知的提高,美洲,特別是美國和加拿大,已成為真菌感染疾病診斷工具的成熟地區。美洲的特點是擁有強大的研究機構和醫療基礎設施,這有助於及時、準確地診斷各種真菌感染疾病。 PCR 和次世代定序儀等診斷技術的進步正在加速美洲的診斷過程、提高準確性並減少潛在的致命風險。在歐洲,真菌感染疾病的盛行率正在顯著增加,罪魁禍首是老年人和免疫抑制患者。對真菌感染疾病的認知不斷提高,增加了對有效診斷工具的需求。歐洲地區的旅行和移民正在增加,導致各種真菌病原體的招募和傳播。因此,醫療保健專業人員正在採用創新的真菌感染疾病診斷方法來有效管理這些高風險環境中潛在的疫情爆發。該地區的特點是研發投資龐大,新興企業數量不斷增加。亞太地區真菌感染疾病的發生率正在迅速增加,這主要是由於人口密度的增加和有利於真菌生長的氣候條件。由於醫療成本上升和患者意識增強,以中國、日本和印度為中心的亞太地區擁有巨大潛力。
FPNV定位矩陣
FPNV 定位矩陣對於評估真菌感染疾病診斷市場供應商的定位至關重要。此矩陣提供了對供應商的全面評估,並檢驗了與商務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果,供應商被分為代表其成功程度的四個像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對真菌感染疾病診斷市場中供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻,您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他關鍵指標。此外,該分析還提供了對該細分市場競爭力的寶貴見解,包括研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊,供應商可以做出更明智的決策並製定有效的策略,以在市場競爭中保持領先地位。
策略分析與建議
策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對真菌感染疾病診斷市場當前地位的全面評估使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析,以確定核心優勢和需要改進的領域。
[183 Pages Report] The Fungal Infections Diagnosis Market size was estimated at USD 2.09 billion in 2023 and expected to reach USD 2.23 billion in 2024, at a CAGR 6.96% to reach USD 3.35 billion by 2030.
Fungal infections, or mycosis, refer to infections or diseases caused by a fungus species (yeast or mold). Fungal infections are most commonly observed on the skin or nails, but fungi can also cause infections in the mouth, throat, lungs, and urinary tract. Fungal infections come in different forms, such as ringworm athlete's foot, toenail fungus, yeast infections, and jock itch. Diagnosis of fungal infection primarily relies on methodologies such as microscopic examination of clinical samples, histopathology, culture, X-rays, MRI, or CT imaging. The rising incidences of fungal infections across the world have led to a surge in demand for effective disease detection technologies. Furthermore, government initiatives promoting awareness of fungal infection management and efforts to expand access to healthcare facilities have led to rising adoption of fungal infection diagnosis. However, the complexity of molecular and genetic fungal infection diagnosis and the lack of skilled medical and clinical personnel impeded the growth of fungal infection diagnosis solutions. Additionally, inaccurate or inconsistent diagnosis results and stringent regulations pertaining to product approval also pose challenges for fungal infection diagnosis devices, solutions, and services. However, major players are rapidly expanding investments in R&D initiatives to improve the capabilities and accuracy of diagnosis technologies. Advances in imaging technologies enhanced digital solutions for remote diagnosis and the introduction of artificial intelligence in rapid diagnostic techniques present opportunities for growth.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 2.09 billion |
Estimated Year [2024] | USD 2.23 billion |
Forecast Year [2030] | USD 3.35 billion |
CAGR (%) | 6.96% |
Regional Insights
The Americas, specifically the US and Canada, present a mature region for fungal infections diagnostic tools, attributable to the increased public consciousness about fungal infections. Americas is characterized by the presence of robust research institutions and medical infrastructure, contributing to the timely and accurate diagnosis of various fungal infections. The technological advancements in diagnostic techniques, including PCR and next-generation sequencing, have accelerated the diagnosis process, improved accuracy, and reduced the potential risk of fatality in the Americas region. In Europe, the spread of fungal infections shows a significant increase, mostly attributed to the elderly population and those with immunosuppressive conditions. There is a rising demand for effective diagnostic tools driven by increased awareness about fungal infections. European region exhibits a rise in travel and migration, which contributes to the introduction and spread of various fungal pathogens. Medical practitioners, therefore, adopt innovative fungal infection diagnostics to manage the potential outbreaks in this high-risk environment effectively. Significant investments in R&D and a growing number of start-ups characterize this region. Asia-Pacific (APAC) region is witnessing an upsurge in the incidence of fungal infections, primarily due to escalating population density and climatic conditions that favor fungal growth. The APAC region, chiefly China, Japan, and India, shows immense potential due to escalating healthcare expenditure and a surge in patient awareness.
Market Insights
The market dynamics represent an ever-changing landscape of the Fungal Infections Diagnosis Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Fungal Infections Diagnosis Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Fungal Infections Diagnosis Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
University of Minnesota Research Team Successfully Tests New Antifungal Therapy For Fungal Meningitis
A research team at the University of Minnesota tested a new antifungal therapy for the treatment of fungal meningitis. The study involves a combination of drugs, which shows promising results in treating fungal infections. This discovery is significant as it could potentially offer new treatment options for individuals affected by fungal infections. The findings of this research offer further advancements in antifungal therapies, providing hope for improved patient outcomes and quality of life. [Published On: 2023-08-22]
Applied BioCode Announces the Launch of the Fungal Panel Assay for Research Use
Applied BioCode introduced the Fungal Panel Assay, a cutting-edge diagnostic tool for the accurate identification of fungal infections. Built on their innovative MultiCode-RTx technology, this assay offers reliable detection and precise identification of pathogens. It is designed for research use and can be employed on a variety of biological samples, including blood, saliva, urine, and tissue. With its ability to deliver maximum test capability from minimal input material, the Fungal Panel Assay can help fight against fungal infections. [Published On: 2023-06-12]
University of Arizona Researchers to Help Track Deadly Fungus in Arizona Wastewater
The University of Arizona researchers identified and monitored a dangerous fungal infection known as Candida auris in the wastewater of Arizona. This particular strain of fungus is resistant to drugs and has the potential to cause severe infections, which can be fatal. The researchers have developed precise and accurate tools to track the presence of this fungus, enabling informed decisions regarding public health. Their work contributes to the development of improved policies for the detection and prevention of such hazardous fungal infections. [Published On: 2023-04-11]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Fungal Infections Diagnosis Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Fungal Infections Diagnosis Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alexion Pharmaceuticals, Inc., Amgen Inc., Associates of Cape COD, Inc. by Seikagaku Group company, Astellas Pharma Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., BioMerieux SA, Bruker Corporation, Danaher Corporation, Eli Lilly and Company, ELITech Group, Eurofins Viracor, LLC, F. Hoffmann-La Roche AG, Hologic, Inc., Immununexpress Inc., IMMY, InBios International, Inc., Laboratory Corporation of America Holdings, Merck KGaA, Norgen Biotek Corp., PerkinElmer, Inc., Polysciences, Inc., Qiagen N.V., Siemens Healthineers, Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific Inc..
Market Segmentation & Coverage